Watanabe Takako, Chinen Takayuki, Nakachi Norishige, Nakamoto Manabu, Uchima Nobufumi, Hirata Tetsuo, Hokama Akira, Kinjo Nagisa, Kinjo Fukunori, Fujita Jiro
The First Dept. of Internal Medicine, University of the Ryukyus.
Gan To Kagaku Ryoho. 2007 Mar;34(3):419-22.
An 80-year-old man was admitted to our hospital for treatment of recurrent esophageal cancer in December, 2004. He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy). Afterwards, lymph nodes recurred, and two courses of CDGP/vindesine were given. Then, the primary lesion showed a complete response (CR), and lymph nodes a partial response (PR). In December, 2004, paraesophageal lymph nodes were enlarged to the size of 7 cm. On admission, because of renal disturbance and dementia with advanced age, we chose chemotherapy with TS-1 (100 mg/body/day, three weeks of administration, then two weeks of withdrawal). He had adverse effects of hematotoxicity of grade 3, and non-hematotoxicity of grade 1. He received 6 courses of this regimen and eventually showed CR. Serum SCC was decreased from 4.7 ng/mL to 0.9 ng/mL. At present,the lesions have not recurred during the follow-up for 18 months.
一名80岁男性于2004年12月因复发性食管癌入院治疗。他于2002年10月被诊断为IVa期食管癌（T2N4M0），并接受了放化疗（奈达铂（CDGP）/5-氟尿嘧啶（5-FU）共6个疗程+60 Gy）。之后，淋巴结复发，给予2个疗程的CDGP/长春地辛治疗。随后，原发灶显示完全缓解（CR），淋巴结显示部分缓解（PR）。2004年12月，食管旁淋巴结增大至7 cm大小。入院时，由于肾功能障碍和高龄痴呆，我们选择了替吉奥（TS-1）化疗（100 mg/体/天，给药3周，然后停药2周）。他出现了3级血液毒性和1级非血液毒性不良反应。他接受了6个疗程的该方案治疗，最终显示CR。血清鳞状细胞癌抗原（SCC）从4.7 ng/mL降至0.9 ng/mL。目前，在18个月的随访期间病变未复发。
